Latest news and articles about semaglutide
Total: 1 articles found
U.S. markets opened slightly lower as gains in GLP‑1 weight‑loss drug makers were offset by weakness in memory stocks. Novo Nordisk and Eli Lilly rose on continued enthusiasm for semaglutide‑class therapies, while Hims & Hers plunged after facing litigation over a generic version. Micron fell amid renewed pressure on cyclical tech names.
